Cabozantinib Improves Survival in RCC Patients With Bone Metastases
Cabozantinib (Cabometyx) was associated with an improvement in overall survival and progression-free survival compared with everolimus (Afinitor) in pretreated patients with advanced RCC with bone metastases at baseline.
Source: OncLive